Clinical Trial

Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 20, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.
Trial Details
NCT Number NCT06605755
Lead Sponsor Jiangsu Province Centers for Disease Control and Prevention
Conditions Pertussis, Diphtheria, Tetanus, Haemophilus Influenzae Type B Infection, Polio
Enrollment 785 participants
Start Date 2024-09-05
Primary Completion 2025-12 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2024-09-20